Periorbital edema

    La Roche-Posay
  • May 2022
  • 15min

Therapeutic classes inducing this adverse event
KIT inhibitor, MEK inhibitor

Periorbital edema

CTCAE V5.0

Soft or non-pitting

SIMPLIFIED GRADING

Asymptomatic

Soft edema


References

Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

CTCAE V5.0

Indurated or pitting edema; topical intervention indicated

SIMPLIFIED GRADING

Indurated or pitting edema


References

Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

CTCAE V5.0

Edema associated with visual disturbance; increased intraocular pressure, glaucoma or retinal hemorrhage; optic neuritis;diuretics indicated; operative intervention indicated

SIMPLIFIED GRADING

Affects eye


References

Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

Browse for more adverse events